Bristol-Myers Squibb Co. and Tsinghua University have entered into a collaboration to discover therapeutic agents against novel targets for autoimmune diseases and cancers.
The collaboration brings together BMS and Tsinghua University’s scientific expertise and capabilities with a focus on validating new targets and generating early drug candidates for clinical development.
Under the collaboration, The Innovation Center for Immune Therapy of Tsinghua University will conduct research on projects and BMS will have an option to exclusively license therapeutic agents discovered by Tsinghua University.
The collaboration is an expansion of an existing relationship between Bristol-Myers Squibb and Tsinghua University that began in 2012, which focused on autoimmune target discovery, structural biology research, as well as the science of mapping the 3D protein structure of biological molecular targets.
